Zobrazeno 1 - 10
of 1 098
pro vyhledávání: '"Settore MED/35 - Malattie Cutanee E Veneree"'
Autor:
Maria Mannino, Alfredo Piccerillo, Emi Dika, Sabina Vaccari, Pietro Quaglino, Marco Rubatto, Caterina Longo, Stefania Borsari, Giovanni Pellacani, Maria Concetta Fargnoli, Chiara Caponio, Giuseppe Argenziano, Giulia Briatico, Luca Bianchi, Cosimo Di Raimondo, Pier Giacomo Calzavara Pinton, Iris Zalaudek, Alessandro Di Stefani, Ketty Peris
Publikováno v:
Dermatology. :1-7
Background: Advanced cutaneous squamous cell carcinoma (aCSCC) represents an area of unmet clinical need, with no standardized treatments until the recent approval of immune checkpoint inhibitors (ICIs). Objectives: The aim of the study was to descri
Autor:
Vasiliki A. Nikolaou, Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freites-Martinez, Konstantinos Lallas, Maria Concetta Romano, Chrysa Oikonomou, Michela Starace, Meletios A. Dimopoulos, Athanassios Kyrgidis, Elizabeth Lazaridou, Priscila Giavedoni, Maria Carmela Annunziata, Ketty Peris, Maria Echeverría, Emilio Lopez-Tujillo, Konstandinos Syrigos, Chryssoula Papageorgiou, Sebastian Podlipnik, Gabriella Fabbrocini, Ana C. Torre, Christina Kemanetzi, Lorena Villa-Crespo, Aimilios Lallas, Alexander J. Stratigos, Vincent Sibaud
Publikováno v:
British Journal of Dermatology. 187:962-969
Summary Background Cutaneous immune-related adverse events (irAEs) represent the most frequent toxicities induced by immune checkpoint inhibitors (ICIs). Objectives To investigate clinical associations of cutaneous toxicities induced by different ICI
Autor:
Andrew Blauvelt, Richard G. Langley, Jean-Philippe Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew E. Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard B. Warren, Eric Simpson, Kristian Reich
Publikováno v:
Journal of the American Academy of Dermatology. 87:815-824
Additional long-term treatments are needed for moderate-to-severe atopic dermatitis (AD). An ongoing, open-label, 5-year extension trial, ECZTEND (NCT03587805), assesses tralokinumab plus optional topical corticosteroids in participants from previous
Autor:
Angela L. Bosma, Annelie H. Musters, Manja Bloem, Louise A. A. Gerbens, Maritza A. Middelkamp‐Hup, Eva Haufe, Jochen Schmitt, Sebastien Barbarot, Julien Seneschal, Delphine Staumont‐Sallé, Emma K. Johansson, Maria Bradley, Laura B. von Kobyletzki, Ida Vittrup, Iben Frier Ruge, Jacob P. Thyssen, Christian Vestergaard, Marina de Vega, Ignacio García‐Doval, Andrea Chiricozzi, Luca Stingeni, Piergiacomo Calzavara‐Pinton, Michael R. Ardern‐Jones, Nick J. Reynolds, Carsten Flohr, Phyllis I. Spuls
Publikováno v:
Bosma, A L, Musters, A H, Bloem, M, Gerbens, L A A, Middelkamp-Hup, M A, Haufe, E, Schmitt, J, Barbarot, S, Seneschal, J, Staumont-Sallé, D, Johansson, E K, Bradley, M, von Kobyletzki, L B, Vittrup, I, Frier Ruge, I, Thyssen, J P, Vestergaard, C, de Vega, M, García-Doval, I, Chiricozzi, A, Stingeni, L, Calzavara-Pinton, P, Ardern-Jones, M R, Reynolds, N J, Flohr, C & Spuls, P I 2023, ' Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce ', Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 37, no. 1, pp. 123-136 . https://doi.org/10.1111/jdv.18566
Journal of the European Academy of Dermatology and Venereology, 37(1), 123-136. Wiley-Blackwell
Bosma, A L, Musters, A H, Bloem, M, Gerbens, L A A, Middelkamp-Hup, M A, Haufe, E, Schmitt, J, Barbarot, S, Seneschal, J, Staumont-Sallé, D, Johansson, E K, Bradley, M, von Kobyletzki, L B, Vittrup, I, Frier Ruge, I, Thyssen, J P, Vestergaard, C, de Vega, M, García-Doval, I, Chiricozzi, A, Stingeni, L, Calzavara-Pinton, P, Ardern-Jones, M R, Reynolds, N J, Flohr, C & Spuls, P I 2023, ' Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce ', Journal of the European Academy of Dermatology and Venereology, vol. 37, no. 1, pp. 123-136 . https://doi.org/10.1111/jdv.18566
Journal of the European Academy of Dermatology and Venereology, 37(1), 123-136. Wiley-Blackwell
Bosma, A L, Musters, A H, Bloem, M, Gerbens, L A A, Middelkamp-Hup, M A, Haufe, E, Schmitt, J, Barbarot, S, Seneschal, J, Staumont-Sallé, D, Johansson, E K, Bradley, M, von Kobyletzki, L B, Vittrup, I, Frier Ruge, I, Thyssen, J P, Vestergaard, C, de Vega, M, García-Doval, I, Chiricozzi, A, Stingeni, L, Calzavara-Pinton, P, Ardern-Jones, M R, Reynolds, N J, Flohr, C & Spuls, P I 2023, ' Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce ', Journal of the European Academy of Dermatology and Venereology, vol. 37, no. 1, pp. 123-136 . https://doi.org/10.1111/jdv.18566
Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common goal to provide long-term
Autor:
Alberto Corrá, Francesca Barei, Giovanni Genovese, Martina Zussino, Cristina B. Spigariolo, Elena B. Mariotti, Lavinia Quintarelli, Alice Verdelli, Marzia Caproni, Angelo V. Marzano
Publikováno v:
The Journal of Dermatology. 50:229-233
Pemphigus is a group of blistering disorders characterized by the formation of intraepithelial blisters in skin and mucous membranes induced by the binding of circulating autoantibodies to intercellular adhesion molecules. The pathogenesis is complex
Autor:
Laura Calabrese, Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Alessandra D’Amore, Ketty Peris
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 18:347-355
Atopic dermatitis (AD) is the most common inflammatory skin disorder. Despite the high disease burden, the therapeutic options are limited and their efficacy in controlling AD might be partially satisfactory.Most of the key mediators in AD pathogenes
Publikováno v:
British Journal of Dermatology. 186:925-941
The interleukin (IL)-1 family of cytokines is a central regulator of a myriad of immunological responses. It comprises several cytokines, including those belonging to the IL-1, IL-36 and IL-18 subfamilies, as well as IL-33. The IL-1 family primarily